Table 4.
Relative dose intensity and adverse events during neoadjuvant chemotherapy
| RDI, % (mean ± SD) | P a | Hematological adverse events (Grade 3 or 4), N | P b | |
|---|---|---|---|---|
| WHO BMI classification, kg/m2 | ||||
| Underweight (BMI < 18.5; n = 18) | 100 ± 0.0 | 0.19 | 2 | 0.09 |
| Normal range (18.5 ≤ BMI < 25; n = 111) | 98.9 ± 3.8 | 19 | ||
| Overweight (25 ≤ BMI <30; n = 35) | 99.9 ± 0.2 | 4 | ||
| Obesity (BMI ≥ 30; n = 8) | 98.6 ± 1.9 | 3 | ||
RDI, relative dose intensity; SD, standard deviation; WHO, World Health Organization; BMI, body mass index.
a
One‐way analysis of variance.
b
Chi square test.